Report: Current Stock Reports

Recommendation of Ryvu’s project for funding by the Medical Research Agency
June 13, 2023

Publication of the updated clinical and preclinical data on RVU120
June 9, 2023

Correction of the current report on the convening of the Company’s Annual General Meeting
May 26, 2023

Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program
May 25, 2023

Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program
May 25, 2023

Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program
May 25, 2023

Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program – Article 19 of MAR
May 25, 2023

Notification from a person discharging managerial responsibilities in the Company – Article 19 of MAR
May 23, 2023

Convening the Ordinary General Shareholders Meeting of Ryvu Therapeutics S.A.
May 18, 2023

Notification from PTE Allianz Polska S.A. of a change in its share in the total number of votes in the Company
May 16, 2023

New clinical and preclinical data on RVU120 to be presented at the upcoming 2023 European Hematology Association Congress
May 11, 2023

Conclusion of an agreement for the issuance of subscription warrants to the European Investment Bank
May 5, 2023

Conclusion of the agreements concerning Phase II start-up services for RVU120 clinical studies in AML/HR-MDS
April 20, 2023

Notification from a person discharging managerial responsibilities in the Company – Article 19 of MAR
April 12, 2023

Notice of termination regarding Option, License and Collaboration Agreement with Galapagos NV
April 6, 2023

Change of publication date of the annual report for 2022
March 10, 2023

Conclusion of an agreement concerning the operational execution of Phase II of Phase I/II clinical trial of RVU120 in Patients with Relapsed/Refractory Solid Tumors
March 2, 2023

Receipt from a person discharging managerial responsibilities in the Company of a correction to the Article 19 MAR notification
February 6, 2023

Notification from a person discharging managerial responsibilities in the Company – Article 19 of MAR
February 3, 2023

Notification from a person discharging managerial responsibilities in the Company – Article 19 of MAR
February 3, 2023